TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31545115

Group type: EXPERIMENTAL
Intervention: Parent-focused stress management intervention (four individual sessions with a community wellness coach over 3 months, supplemented with weekly text messaging and twice monthly group sessions for 6 months)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard care based on the guidelines of the National Institutes of Health
Number of subjects: 217
Study: 30722059

Group type: EXPERIMENTAL
Intervention: Lefamulin 150 mg IV every 12 hours
Number of subjects: 551

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg IV every 24 hours
Number of subjects: 551
Study: 28629896

Group type: COMPARATOR
Intervention: CRT (chemoradiotherapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CRT plus panitumumab
Number of subjects: 60
Study: 25887528

Group type: EXPERIMENTAL
Intervention: NL plus earplugs and eye masks (NLEE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NL plus melatonin (NLM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NL night
Number of subjects: 40
Study: 23969143

Group type: EXPERIMENTAL
Intervention: Collaborative care program including 2 days of intensive training, a stepped care protocol, depression management toolkit, and scheduled meetings with a consultant psychiatrist.
Number of subjects: 227

Group type: COMPARATOR
Intervention: Usual care by primary care physicians (PCPs).
Number of subjects: 227
Study: 21432728

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Combined intervention (self-efficacy and self-affirmation)
Number of subjects: 677

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 677
Study: 19746673

Group type: EXPERIMENTAL
Intervention: Solubilized 5% BPO gel
Number of subjects: 65

Group type: COMPARATOR
Intervention: 5% BPO/1% clindamycin
Number of subjects: 65
Study: 17760245

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 102

Group type: COMPARATOR
Intervention: Breast feeding
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 15007119

Group type: EXPERIMENTAL
Intervention: Flupirtine (FLU), n = 13
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLA), n = 15
Number of subjects: 28
Study: 11095452

Group type: EXPERIMENTAL
Intervention: sc insulin (INS)
Number of subjects: 9
Study: 9347196

Group type: EXPERIMENTAL
Intervention: Wpos (positive work)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wneg (negative work)
Number of subjects: 12
Study: 8341987

Group type: EXPERIMENTAL
Intervention: Omeprazole and amoxycillin combination therapy (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole monotherapy (n = 30)
Number of subjects: 60
Study: 3088652

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 8 a.m.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 11 p.m.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 2 a.m.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.25 mg at 5 a.m.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 29488152

Group type: EXPERIMENTAL
Intervention: DS-8500a 25 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DS-8500a 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26934259

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (n=278; maximum dose, 50 U of degludec/1.8 mg of liraglutide)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Insulin glargine (n=279; no maximum dose)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide
Number of subjects: 557
Study: 24628438

Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (nonadaptive) training
Number of subjects: 51
Study: 23509088

Group type: EXPERIMENTAL
Intervention: Low coffee consumption (< 200 ml/day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Moderate coffee consumption (200‐450 ml/day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: High coffee consumption (> 450 ml/day)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Boiled Greek type of coffee
Number of subjects: 142
Study: 20077301

Group type: EXPERIMENTAL
Intervention: High nitrate levels in drinking water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lowest tertile of nitrate levels in drinking water
Number of subjects: 0
Study: 18768350

Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 3834

Group type: COMPARATOR
Intervention: Losartan 50 mg (antihypertensive dose)
Number of subjects: 3834
Study: 16847534

Group type: EXPERIMENTAL
Intervention: High BrAC (Study 1)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Alcohol condition (Study 2)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo condition (Study 2)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No-alcohol condition (Study 2)
Number of subjects: 152
Study: 12756157

Group type: EXPERIMENTAL
Intervention: Nurse facilitator (supervised nurse to initiate and titrate beta-blockers)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Provider and patient notification (computerized provider reminders and patient letters advocating beta-blockers)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control (provider education)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Nurse facilitator
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control
Number of subjects: 169

Group type: COMPARATOR
Intervention: Provider and patient notification
Number of subjects: 169
Study: 11307807

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OA)
Number of subjects: 433
Study: 9196608

Group type: EXPERIMENTAL
Intervention: Once daily (OD) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Twice daily (BID) subcutaneous injections of GH at a total dose of 6 IU/m2/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both OD and BID groups
Number of subjects: 19
Study: 8198761

Group type: EXPERIMENTAL
Intervention: Controlled-release formulation (Orfil retard enteric coated tablet)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plain tablet (reference drug)
Number of subjects: 24
Study: 3798537

Group type: EXPERIMENTAL
Intervention: Russell's viper venoid (0.5 ml subcutaneous injection followed by two booster injections at four-week intervals)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (6 subjects)
Number of subjects: 12
Study: 29729393

Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 27756495

Group type: EXPERIMENTAL
Intervention: Master of Taste (MT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Master of Taste + NAO (MT + NAO)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 24788028

Group type: EXPERIMENTAL
Intervention: Providing case management
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Offering transportation vouchers or free parking
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Offering outreach
Number of subjects: 638
Study: 23197780

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) with insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Akt inhibitor (wortmannin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FGFR-1 inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: EGFR activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: ErbB2 inhibition
Number of subjects: 0
Study: 19497708

Group type: EXPERIMENTAL
Intervention: Quiet conditions using a cellular phone (QCP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Quiet conditions using cellular phone with earpiece (QCPE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Noisy conditions using cellular phone (NCP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Noisy conditions using cellular phone with earpiece (NCPE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All quiet conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noisy conditions
Number of subjects: 20
Study: 18605892

Group type: EXPERIMENTAL
Intervention: Fluoride varnish application (Fluoridin, Voco) at baseline, 3 months, and 6 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no professional fluoride application)
Number of subjects: 92
Study: 15784942

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-modified glass ionomer cement (CHXGIC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional glass ionomer cement (GIC)
Number of subjects: 120
Study: 11124748

Group type: EXPERIMENTAL
Intervention: Behenate oil
Number of subjects: 7

Group type: COMPARATOR
Intervention: Palm oil
Number of subjects: 7

Group type: COMPARATOR
Intervention: High-oleic acid sunflower oil
Number of subjects: 7
Study: 9664583

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) using Itrel II System pulse-generator
Number of subjects: 27
Study: 8145004

Group type: EXPERIMENTAL
Intervention: Hemofer (2 tablets = 18 mg iron/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erco-Fer (1 tablet = 60 mg iron/day)
Number of subjects: 0
Study: 3071435

Group type: EXPERIMENTAL
Intervention: MaxEPA fish lipid concentrate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 86
Study: 1948094

Group type: EXPERIMENTAL
Intervention: Defibrotide 400 mg b.i.d. for 6 months
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Defibrotide 800 mg o.d. for 6 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Defibrotide 800 mg
Number of subjects: 193
Study: 29653

Group type: EXPERIMENTAL
Intervention: Trimepranol (10-14 mg/twice daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (50 mg every second day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of trimepranol and chlorthalidone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trimepranol
Number of subjects: 18
Study: 31321636

Group type: EXPERIMENTAL
Intervention: Intervention group (n=108) received a 10-min video clip and brief counseling in addition to an education booklet.
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (n=136) received only an education booklet.
Number of subjects: 244
Study: 28193197

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (PEI)
Number of subjects: 17
Study: 26335089

Group type: EXPERIMENTAL
Intervention: Financial incentives of £15 (US $23) for each long-acting injectable antipsychotic (LAI) received.
Number of subjects: 141

Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Higher total amount of incentives offered.
Number of subjects: 141
Study: 22446301

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20403652

Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy with down‐grafting and interpositioning of bone (10 patients)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Raising the sinus floor with onlay bone grafting (17 patients)
Number of subjects: 27
Study: 19796583

Group type: EXPERIMENTAL
Intervention: Primary open reduction and internal fixation (PORIF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Primary arthrodesis (PA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (PORIF and PA)
Number of subjects: 40
Study: 17822565

Group type: EXPERIMENTAL
Intervention: Intervention group (group I, n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (group C, n = 16)
Number of subjects: 33
Study: 15514527

Group type: EXPERIMENTAL
Intervention: Cefazolin for duration of tube thoracostomy placement (Group A)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Cefazolin for 24 hours (Group B)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 224
Study: 11133628

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 50
Study: 9562282

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (Eprex)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7880938

Group type: EXPERIMENTAL
Intervention: Arginine (ARG) 30 g infused over 30 min starting at 0 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) 120 mg orally, 60 min before GHRH administration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GHRH administration
Number of subjects: 11
Study: 3067566

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31630113

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) tools implementation
Number of subjects: 60
Study: 27935166

Group type: EXPERIMENTAL
Intervention: 3D regimen (ombitasvir, paritaprevir/ritonavir, dasabuvir) with or without ribavirin
Number of subjects: 2027
Study: 25957039

Group type: EXPERIMENTAL
Intervention: 2C3L
Number of subjects: 146

Group type: COMPARATOR
Intervention: stepwise
Number of subjects: 146
Study: 23792241

Group type: EXPERIMENTAL
Intervention: Plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 313
Study: 21924552

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 18270032

Group type: EXPERIMENTAL
Intervention: 3-D segmentation algorithm for lung nodules in CT images
Number of subjects: 107
Study: 16943402

Group type: EXPERIMENTAL
Intervention: Neurostimulation of the subthalamic nucleus
Number of subjects: 156

Group type: COMPARATOR
Intervention: Medication alone (Control)
Number of subjects: 156
Study: 14659065

Group type: EXPERIMENTAL
Intervention: Emergency endoscopy (group A)
Number of subjects: 91
Study: 11214707

Group type: EXPERIMENTAL
Intervention: DDD pacing or oral theophylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 0
Study: 9598259

Group type: EXPERIMENTAL
Intervention: Ringer's solution (25 ml.kg-1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dextran 3% (10 ml.kg-1)
Number of subjects: 19
Study: 7888692

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) and dietary carbohydrate (CHO) counting
Number of subjects: 23

Group type: COMPARATOR
Intervention: Behavioral program without SMBG and CHO counting
Number of subjects: 23
Study: 3170960

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.27 mmol/kg body weight)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31570296

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (50 mg or 100 mg daily for adolescents)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (105.7 mg mean daily for adults)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide
Number of subjects: 73
Study: 28010994

Group type: EXPERIMENTAL
Intervention: One-to-one pelvic floor muscle training (five physiotherapy appointments over 16 weeks, annual review) plus Pilates-based pelvic floor muscle training classes and a DVD for home use
Number of subjects: 414

Group type: COMPARATOR
Intervention: Prolapse lifestyle advice leaflet
Number of subjects: 414
Study: 25494864

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity allele score (GS‐InSens)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Insulin secretion allele score (GS‐InSec)
Number of subjects: 96
Study: 23243248

Group type: EXPERIMENTAL
Intervention: Myo-inositol at 0.1%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phytase B at 1,300 acid phosphatase units/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phytase B enriched in 6-phytase A at 300 phytase units/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative control diet (0.304 g of monocalcium phosphate per kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Internal control diet (adjusted NPP content)
Number of subjects: 60
Study: 21884956

Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed hypertension medications upon awakening
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Ingesting ≥1 of prescribed hypertension medications at bedtime
Number of subjects: 3344
Study: 19844206

Group type: EXPERIMENTAL
Intervention: SNPs in ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1 and NTRK2
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: SNPs in ABCB1, SLC6A2 and NTRK2
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: NTRK2-coding SNPs (rs2289657 and rs56142442) and haplotype CAG at rs2289658, rs2289657 and rs2289656
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 536
Study: 16412216

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 6961

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 6961

Group type: COMPARATOR
Intervention: Adherence to lifestyle recommendations
Number of subjects: 6961

Group type: EXPERIMENTAL
Intervention: Cigarette consumption
Number of subjects: 6961
Study: 15311218

Group type: EXPERIMENTAL
Intervention: Chitosan (3 g/day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 11517198

Group type: EXPERIMENTAL
Intervention: Nasal CPAP delivered through binasal (Hudson) prongs
Number of subjects: 87

Group type: COMPARATOR
Intervention: Nasal CPAP delivered through a single nasal prong
Number of subjects: 87
Study: 9369265

Group type: EXPERIMENTAL
Intervention: SR 49059 (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SR 49059 (300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1490537

Group type: EXPERIMENTAL
Intervention: Intervention to improve computerized recording of presenting symptoms and problems/diagnoses
Number of subjects: 7983

Group type: COMPARATOR
Intervention: Control group (manual record)
Number of subjects: 7983
Study: 2417834

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (mol. wt 450,000)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dextran (mol. wt 60,000)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5% plasma protein solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 30923187

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: French non-invasive method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Swedish/COMPERA methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-risk criteria or low-risk stratum at follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inoperable or persistent/recurrent CTEPH
Number of subjects: 0
Study: 29650348

Group type: EXPERIMENTAL
Intervention: Serious game 'The world of EMPA'
Number of subjects: 224

Group type: COMPARATOR
Intervention: Digital information package about disabilities
Number of subjects: 224
Study: 27178047

Group type: EXPERIMENTAL
Intervention: fasiglifam 25 mg once daily
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: fasiglifam 50 mg once daily
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: fasiglifam monotherapy
Number of subjects: 282

Group type: COMPARATOR
Intervention: sulphonylurea combination therapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: fasiglifam (both doses)
Number of subjects: 282
Study: 24731434

Group type: EXPERIMENTAL
Intervention: Active rTMS (high dose left prefrontal repetitive transcranial magnetic stimulation)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 41
Study: 23005919

Group type: EXPERIMENTAL
Intervention: Albuterol MDI with valved spacer
Number of subjects: 31

Group type: COMPARATOR
Intervention: Albuterol MDI with non-valved spacer
Number of subjects: 31
Study: 20473771

Group type: EXPERIMENTAL
Intervention: Trigeminal block with 0.8‐mL lidocaine 2%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Deep sedation and trigeminal injection of 0.8‐mL saline (Control)
Number of subjects: 55
Study: 17912933

Group type: EXPERIMENTAL
Intervention: Aspheric IOLs (Acrysof IQ SN6OWF, Tecnis Z9000, Sofport L161AO)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Spherical IOLs (Acrysof SN6OAT, Sensar AR40e)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Aspheric IOLs
Number of subjects: 250
Study: 16113582

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and gonadotropin-releasing hormone agonist (GnRHa) treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38
Study: 11974545

Group type: EXPERIMENTAL
Intervention: Primary velopharyngoplasty
Number of subjects: 42
Study: 10411034

Group type: EXPERIMENTAL
Intervention: Sequential BCG and epirubicin (group 1)
Number of subjects: 139

Group type: COMPARATOR
Intervention: BCG alone (group 2)
Number of subjects: 139
Study: 9606452

Group type: EXPERIMENTAL
Intervention: Experimental group (patients whose source pharmacy provided preadmission information)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (patients whose source pharmacy did not provide preadmission information)
Number of subjects: 156

Group type: COMPARATOR
Intervention: LTC pharmacists
Number of subjects: 156
Study: 1883257

Group type: EXPERIMENTAL
Intervention: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d) for 2 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Haloperidol at neuroleptic threshold dosages (mean, 3.4 +/- 2.3 mg/d) for 2 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d)
Number of subjects: 106